Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Investigation Report on China's Insulin Aspart Market, 2018-2022 - ResearchAndMarkets.com

Research and Markets
Posted on: 02 Nov 18

The "Investigation Report on China's Insulin Aspart Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The rapid development of the Chinese economy in the past three decades has changed people's dietary habits and reduced physical activities, which leads to an increasing incidence of obesity-related diseases. It is estimated that at the end of 2017, there were more than 100 million diabetic patients in China. The market size of diabetes drugs is also growing in China.

On Dec. 26, 2001, Novo Nordisk announced that Insulin Aspart (trade name: NovoRapid), the first and only insulin analog that can be used with insulin pumps, was approved by the FDA. Insulin Aspart starts working in 10 to 20 minutes after subcutaneous injection and can reduce postprandial blood glucose and glycated hemoglobin (HbA1c).

On the basis of Insulin Aspart, Novo Nordisk developed premixed insulin aspart containing soluble insulin aspart and protaminated insulin aspart of various proportions. The combination of the fast-acting form and the long-acting form allows patients to receive fewer injections over the course of the day. NovoLog Mix 70/30, containing 30% soluble insulin aspart and 70% protaminated insulin aspart, was approved by the FDA in Nov. 2001. Similar NovoLog Mix 50/50 was approved by the FDA in Aug. 2008.

Because there are high technical barriers against the imitation of Insulin Aspart, by Oct. 2018, China's Insulin Aspart market is monopolized by Novo Nordisk's Insulin Aspart (NovoRapid). Several Chinese companies are applying for the CFDA's approval for generic Insulin Aspart. However, the launch of generic drugs will take several years. With an increasing number of diabetic patients, the market size of Insulin Aspart in China will maintain rapid growth in the next few years.

Topics Covered:

  • Situation of diabetes in China
  • Sales of Insulin Aspart in China
  • Prices of Insulin Aspart in China
  • Progress of generic Insulin Aspart in China
  • Prospect of China's Insulin Aspart market from 2018 to 2022

Key Topics Covered:

1 Relevant Concepts of Insulin Aspart

2 Sales of Insulin Aspart in China, 2013-2017

3 Analysis on Major Insulin Aspart Manufacturers in China, 2013-2017

4 Prices of Insulin Aspart in China, 2017-2018

5 Prospect of China's Insulin Aspart Market, 2018-2022

For more information about this report visit https://www.researchandmarkets.com/research/8jlm5v/investigation?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181102005257/en/

Business Wire
www.businesswire.com

Last updated on: 02/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.